When will CMS announce the addition of GLP-1 drugs for obesity to Part D?

Before Jan 20, 2029 If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan X Y then the market resolves to Yes. GLP-1 drugs are already covered under Part D for type 2 diabetes, cardiovascular risk reduction and obstructive sleep apnea. Those indications are outside this market, which turns on coverage for obesity or chronic weight management. Only a completed CMS action that provides the coverage counts, such as a final rule, a finalized model design, or guidance to Part